La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Sofiva GenomicsLtd Bilan de santé

Santé financière contrôle des critères 6/6

Sofiva GenomicsLtd possède un total de capitaux propres de NT$640.7M et une dette totale de NT$0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont NT$775.8M et de NT$135.1M. L'EBIT de Sofiva GenomicsLtd est NT$2.2M ce qui fait que son ratio de couverture des intérêts -9.4. Elle dispose de liquidités et de placements à court terme de NT$123.4M.

Informations clés

Ratio d'endettement

NT$0

Dette

Ratio de couverture des intérêts	-9.4x
Argent liquide	NT$123.42m
Fonds propres	NT$640.72m
Total du passif	NT$135.13m
Total des actifs	NT$775.84m

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

Some Investors May Be Worried About Sofiva GenomicsLtd's (GTSM:6615) Returns On Capital

Apr 14

Estimating The Fair Value Of Sofiva Genomics Co.,Ltd. (GTSM:6615)

Mar 18

Sofiva Genomics Co.,Ltd. (GTSM:6615) Investors Should Think About This Before Buying It For Its Dividend

Feb 24

Should Weakness in Sofiva Genomics Co.,Ltd.'s (GTSM:6615) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Jan 27

Analyse de la situation financière

Passif à court terme: 6615's short term assets (NT$281.0M) exceed its short term liabilities (NT$89.6M).

Passif à long terme: 6615's short term assets (NT$281.0M) exceed its long term liabilities (NT$45.6M).

Historique et analyse du ratio d'endettement

Niveau d'endettement: 6615 is debt free.

Réduire la dette: 6615 had no debt 5 years ago.

Couverture de la dette: 6615 has no debt, therefore it does not need to be covered by operating cash flow.

Couverture des intérêts: 6615 has no debt, therefore coverage of interest payments is not a concern.

Sofiva GenomicsLtd Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Recent updates

Second quarter 2024 earnings released: EPS: NT$0.45 (vs NT$0.20 in 2Q 2023)

Sofiva Genomics Co.,Ltd. to Report Q2, 2024 Results on Aug 14, 2024

Investor sentiment deteriorates as stock falls 21%

Investor sentiment improves as stock rises 17%

Upcoming dividend of NT$0.20 per share

Dividend reduced to NT$0.20

New major risk - Share price stability

Investor sentiment improves as stock rises 16%

First quarter 2024 earnings released: EPS: NT$0.58 (vs NT$0.20 in 1Q 2023)

Sofiva Genomics Co.,Ltd. to Report Q1, 2024 Results on May 15, 2024

New minor risk - Profit margin trend

Sofiva Genomics Co.,Ltd., Annual General Meeting, May 29, 2024

Third quarter 2023 earnings released: EPS: NT$0.27 (vs NT$0.12 in 3Q 2022)

Sofiva Genomics Co.,Ltd. Announces Resignation of Su,Yining as CEO

Sofiva Genomics Co.,Ltd. Announces Resignation of Su,Yining as CEO

Second quarter 2023 earnings released: EPS: NT$0.20 (vs NT$0.28 in 2Q 2022)

Investor sentiment improves as stock rises 18%

Upcoming dividend of NT$1.00 per share at 2.5% yield

Sofiva Genomics Co.,Ltd. Declares Cash Dividend, Payable on July 31, 2023

Investor sentiment improves as stock rises 23%

Full year 2022 earnings released: EPS: NT$2.00 (vs NT$2.68 in FY 2021)

Less than half of directors are independent

Second quarter 2022 earnings: EPS misses analyst expectations

Upcoming dividend of NT$2.00 per share

Sofiva Genomics Co.,Ltd. Announces Cash Dividend, Payable on July 28, 2022

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Less than half of directors are independent

Third quarter 2021 earnings released: EPS NT$0.68 (vs NT$0.28 in 3Q 2020)

Second quarter 2021 earnings released: EPS NT$0.93 (vs NT$0.40 in 2Q 2020)

Upcoming dividend of NT$1.40 per share

First quarter 2021 earnings released: EPS NT$0.42 (vs NT$0.49 in 1Q 2020)

First quarter 2021 earnings released: EPS NT$0.42 (vs NT$0.49 in 1Q 2020)

Investor sentiment improved over the past week

Some Investors May Be Worried About Sofiva GenomicsLtd's (GTSM:6615) Returns On Capital

Full year 2020 earnings released: EPS NT$1.63 (vs NT$2.96 in FY 2019)

Estimating The Fair Value Of Sofiva Genomics Co.,Ltd. (GTSM:6615)

Sofiva Genomics Co.,Ltd. (GTSM:6615) Investors Should Think About This Before Buying It For Its Dividend

Should Weakness in Sofiva Genomics Co.,Ltd.'s (GTSM:6615) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

New 90-day low: NT$50.60

Our Take On The Returns On Capital At Sofiva GenomicsLtd (GTSM:6615)

New 90-day low: NT$51.60

A Look At The Intrinsic Value Of Sofiva Genomics Co.,Ltd. (GTSM:6615)

New 90-day low: NT$54.00

Read This Before Buying Sofiva Genomics Co.,Ltd. (GTSM:6615) For Its Dividend

Third quarter 2020 earnings released: EPS NT$0.28

New 90-day low: NT$55.00

New 90-day low - NT$55.20

New 90-day low - NT$59.00

First half earnings released

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines